T cell non-Hodgkin's lymphomas are a heterogeneous group of lymphomas with poor prognosis, and whose genetic alterations are not well understood. Comparative genomic hybridization (CGH) is a technique that allows the identification of DNA imbalances without cytogenetic studies. We have studied 37 samples from 29 T cell non-Hodgkin's lymphomas (25 peripheral and four lymphoblastic lymphomas) by CGH in order to detect DNA sequence copy number changes of putative importance in the biology and prognosis of these neoplasms. We detected abnormal CGH profiles in 16/27 (59%) of samples at diagnosis, a ratio that increased to 66% (23/37) when we included the relapsed samples. The most common recurrent changes were gains related to the X chromosome, either the whole chromosome or partially the Xq26-27 bands (19%). 
Introduction
T cell lymphomas are a heterogeneous group of nonHodgkin's lymphomas (NHLs) with a highly variable morphology and controversial classification. In Spain, these tumors are less common than those of B cell origin, as occurs in the rest of Europe (10-15% of all NHLs). Moreover, compared with B cell neoplasms, T cell NHLs appear to have a worse prognosis. 1 The genetic data on T cell neoplasms are still limited. Although non-random abnormalities at the cytogenetic level have been described, such as rearrangements involving 14q11, 14q32, 6p23, 1p36, 2 and trisomies of chromosomes X, 3 and 7q, [3] [4] [5] [6] the molecular changes that could play a role in tumoural pathogenesis and progression and in drug resistance remain unknown.
Comparative genomic hybridization (CGH) is a technique allowing the identification of imbalances of the entire genome in terms of DNA copy number with a putative diagnostic and prognostic value that could remain undetected by conventional cytogenetics. Its main advantage with respect to cyto-genetic techniques is that CGH does not need cell culture to obtain metaphases and it allows a global genetic analysis of the genome by passing the examination of a minor cell clone that was not representative of the tumoral genetic profile.
We have performed CGH in 37 samples from 29 patients with T cell NHL, in order to detect DNA sequence copy number changes along all chromosomes. Our results point to specific regions previously described by cytogenetic techniques, as well as other new regions not previously described. Amplification of some genes mapped in one of these regions, detected by Southern and FISH analysis was concordant with the CGH results.
Materials and methods

Patients
High molecular weight DNA was extracted from 37 samples belonging to 29 patients diagnosed of T-NHL; 35 fresh lymph nodes and two bone marrow samples. According to the WHO classification 7 the 29 T cell NHL included 25 peripheral T cell lymphomas (PTCL) (two angioimmunoblastic, three anaplastic large cell, two mycosis fungoides, 17 unspecified and one unclassifiable) and four precursor T cell lymphoblastic lymphomas. The 17 unspecified PTCL corresponded to the pleomorphic and lymphoepithelioid types of the Kiel classification. 8 In seven cases, different samples were obtained at different stages during the evolution of the disease. A summary of clinical data is shown in Table 1 .
Immunohistochemistry
Tissue was routinely fixed in 10% formalin, embedded in paraffin and stained with hematoxylin-eosin (E-H) and Giemsa in thin sections (4 m).
An immunohistochemical study was performed with a streptavidin-biotin peroxidase complex technique using a complete panel of monoclonal antibodies against T and B lymphocytes (CD45, CD3, CD4, CD8, CD20), histiocytes (CD68), dendritic cells (CD21), activation markers (CD30, CD15, EMA) and aggressiveness (MIB1, P53) after heat pretreatment for antigenic retrieval. The two monoclonal antibodies used to consider neoplastic aggressivity, MIB1 and p53 showed nuclear strong positivity, without stained cytoplasms. Immunocytochemistry technique with previous heat antigen retrieval avoids non-specific cytoplasmic discolored patterns. The quantification of MIBI and the expression of P53 protein was determined with an image analyzer (CAS-200, Becton Dickinson) with proliferation index program which provides an accurate and objective method for assessment. P53 overexpression was defined when positive cells were over 10%. P53 staining is absent in reactive lymphoid tissue, and 10% 
PTCL, peripheral T cell lymphoma; AILT, angioimmunoblastic T cell lymphoma; MF, mycosis fungoides; D, diagnosis; R, relapse; CR, complete remission; PI, proliferative index; +, P53 protein levels Ͼ10%; −, P53 protein levels Ͻ10%; ND, no data; TCR, T cell receptor rearrangements; M, monoclonal; P, polyclonal; NA, not available; A, altered CGH profile; N, normal CGH profile.
was accepted as a correct value of expression in high-grade lymphomas. In relation to MIB1, we considered cases under and over 40% of positive cells to correlate with the presence of altered CGH profiles. There is not consensus about precise quantitative values of MIB1 to differentiate low and high grades in T cell lymphomas, but in our experience at over 40-50% a major aggressiveness is expected. 9 Estimates of the proportion of tumoral cells ranged from 60 to 100% in peripheral T-lymphomas and between 90 and 100% in lymphoblastic lymphomas.
TCR (T cell receptor) gene rearrangements
TCR-gamma chain gene rearrangements were performed in all tumors. We used PCR with primers previously described 10 to detect clonal tumor cells in these samples. We carried out two multiplex PCRs with the following primers mixes: mix I contained TCR V2, V3, V4, V8 and V9 and mix II contained TCR V5, V10, V11, and V12. For the J segments, three primers were mixed JGT1-2, JGT3 and JGT4. PCR reactions were performed in 50 l of 1 × PCR buffer (50 mM KCl, 10 mM Tris (pH 8.3), 1.5 mM MgCl 2 ), 200 M of dNTPs, 25 pmol of each primer, 250 ng of DNA, 2.5 U Taq polymerase (Boehringer Mannheim). The amplification cycles consisted on: 45 s at 94°C, 45 s at 54 or 55°C (mix I or mix II) and 45 s at 72°C, followed by final extension of 5 min at 72°C. The PCR products were then resolved in a 9% polyacrylamide gel (19:1 acrylamide:bisacrylamide ratio), and then stained with ethidium bromide.
Comparative genomic hybridization
Comparative genomic hybridization (CGH) was performed according to Kallionemi et al, 11 with some modifications. The tumor (test) and normal (reference) DNAs were labelled with SpectrumGreen and SpectrumOrange fluorochromes by using the nick translation kit from Vysis, IL, USA. All samples were co-hybridized with sex-matched reference DNA. For each group of experiments, positive and negative controls (cases with and without known changes) were analyzed at the same time. Briefly, 200 ng of each labelled DNA were hybridized to normal male metaphase spreads in the presence of 15 g of Cot-1 DNA, for 3 days. After washes, chromosomes were counterstained with DAPI in an antifade solution.
Digital image analysis and interpretation of CGH results
All CGH experiments were performed twice and independently by two of us. Slides were analyzed with a Nikon epifluorescence microscope equipped with a charged coupled device camera. A minimum of seven to 10 metaphases per hybridization and case were analyzed using two image analysis systems (Quips, Vysis; and Cytovision, Applied Imaging, UK) that can process three-color images, green for the tumor DNA hybridization, red for the normal reference DNA hybridization and blue for the DNA counterstain.
The green and red fluorescence intensities were calculated and the green-to-red ratio profiles along the chromosome axis were displayed. Ratios greater than 1.20 and less than 0.80 were considered to represent chromosomal gain and loss, respectively. High level amplification was defined as occurrence of fluorescence intensity values in excess of 2.0 and distinct strong localized (band-like) green signal. Telomeric and heterochromatic regions were excluded from the analysis. 12 
DNA probes fluorescence in situ hybridization (FISH)
Direct-fluoresceion isothiocyanate (FITC) and digoxinelabelled probes for the X centromere were cohybridized in separate assays together with some of the same probes of the Xq26 regions that were used for the Southern blot: MAGE1, SH2D1A, MTCP1 and MCF2. These gene probes were first hybridized on to normal metaphase spreads to detect any chimeric signal and to confirm the localization of the signal at Xq26 (data not shown). The probe for gene MAGE1 showed a clear and distinct signal and it was our choice for the tests. Diagnostic FISH assays were then done on paraffin-embedded tissue. Briefly, 5 m sections were cut from the paraffin block and placed on to silanized slides. The tissues were deparaffinized using two changes of xylene and two changes of 100% ethanol, both 10 min each. The samples were then pretreated with a solution of sodium bisulfite (1%) in 2 × SSC, and digested with 10 mg/ml of proteinase K (at 40°C and during 40 min each wash). Denaturation was done in 70% formamide/2 × SSC for 2 min at 72°C. The denatured slides were dehydrated in cold ethanol. The probe mixture was denatured at 75°C for 10 min, applied to the slides, covered and sealed with glass coverslips, and incubated overnight at 37°C. Two washing steps were carried out with 0.4 × SSC/0.1% Nonidet-P40 at 45°C, and, when necessary, detection was performed with avidin FITC anti-digoxigenin solution. The samples were counterstained with DAPI.
Hybridization signals were visualized using an Olympus microscope, and images were captured on a CCD camera, using Cytovision image software. Two hundred nuclei that showed both green (X centromere) and red (genes mapped at Xq26) signals were counted.
Southern blot hybridization
In order to confirm these gains at the molecular level, Southern blot was performed in three tumors that had gains of the entire X chromosome or specific gains of the Xq26-27 region as revealed by CGH. Two tumor samples with normal CGH profiles, and two normal peripheral blood samples were also analyzed. DNA was digested separately with two different Leukemia restriction enzymes, HindIII and EcoRI. After electrophoresis, the DNA was transferred to a nylon membrane and then hybridized using radioactive labelled probes from genes located at Xq26-28 (SH2D1A, MCF2, MAGE1 and MTCP1) obtained from the following IMAGE clones: 1032031, 1755974, 1757557 and 701515, respectively. First, these clones were grown and DNA was extracted following standard methods. The inserts were sequenced to confirm the corresponding sequence of each gene before they were used as probes. After digestion with HindIII enzyme, hybridization with MCF2 probe generated two fragments of 4.6 and 1.8 kb, and with SH2D1A probe, a 3.4 kb fragment. Digestion with EcoRI and hybridization with MAGE and MTCP1 probes generated fragments of 4.4 and 4.6 kb, respectively. The intensity of bands was quantified by means of densitometric analysis. To estimate the gained copy number, the results were standarized with the results obtained from a control gene (␤-actin) and compared to normal samples. The sex of the patients included in the analysis was always considered in order to determine the level of amplification.
Statistical analysis
We used the two coils Fisher exact test with a confidence interval of 95% for detecting any possible significant associations between the clinical parameters and the CGH results.
Results
All tumoral samples showed an immunophenotype compatible with T cell lymphomas, and most of them (63%) also showed monoclonal rearrangements of the TCR-gamma chain gene (Table 1) .
CGH analysis revealed a 59% of samples at diagnosis (16/27 cases) with chromosomal aberrations. This percentage increased to 66% when the additional relapse samples were included (23/37 samples) ( Table 1 ). The most frequent changes included gains at chromosome X (19%), 19 (10%), 17 (10%), 20 (10%) and gain of 9q34 band (10%) and complete loss or partial deletion of chromosome 13 (10%). Other less common alterations were specific gains of 11q13 (8%), and 5p15 band (8%) and gains at chromosome 7 with the commonly gained region at 7q32-ter (8%) (Figure 1 ). Ten of 19 patients showed multiple aberrations in different chromosomes, but a single alteration was found in the remaining nine patients. These single alterations included the gain of the X chromosome (case 1), gain of the 3q27-qter region (case 2), gains at 7q (case 27) and two lymphomas (cases 6 and 8) that shared the gain of 5p15 region as the only alteration at diagnosis. Other single alterations were found in some lymphomas, but they constituted unique events not shared by other tumors.
In seven cases, serial samples were obtained periodically. Changes in the CGH profile were observed in four of them (cases 1, 7, 8, 22 ). Patients 1 and 22 showed first a normal CGH profile, but the gain of whole chromosome X appeared in the second relapse of patient 1 and multiple alterations were found in the relapse sample of patient 22. In patient 7, the gain of the X chromosome was present at diagnosis and was maintained in two relapse samples. In case 8, gain of the 5p15 band was detected at diagnosis, and additional changes were observed at relapse. In the other patients (cases 15, 16, 26) a normal profile was found in the different stages of the disease.
In two lymphomas (cases 22 and 25) we could detect high level amplifications. Case 22 showed a very complex CGH profile at relapse that included gains and losses at different chromosomes and clear amplification signal at 17q12-q21 bands (Figure 2 ). Case 25 presented amplification of 19q13.1 band.
Association of CGH results with the histological and clinical features
The presence of chromosomal alterations detected by CGH in our series does not seem to be associated with any specific subtype of T cell lymphomas (Table 1) . Two thirds of both types of peripheral T cell and lymphoblastic lymphomas harbored genetic changes. We did not find CGH gains or losses in the two cases of mycosis fungoides analyzed. In addition, the most relevant aberrations were found in almost all subtypes analyzed.
We tried to correlate CGH results statistically with the following clinical data: clinical stage, histological subtype, overexpression of p53, and PI. An abnormal CGH profile was associated with more advance clinical stages (P = 0.03389), with overexpression of P53 (P = 0.037), and with PI over 40% (P = 0.03661) ( Table 2) . No statistically significant association was found for the histological subtype.
Gene and FISH analysis
Southern blot analysis of some genes located in Xq26-28, which is the minimal region involved in gains affecting chromosome X in these lymphomas, confirmed the presence of gains of genetic material at the molecular level. We selected MCF2, SH2D1A, MAGE1 and MTCP1 genes because of their possible implication in different neoplasias. Three of the cases (tumour 7 at diagnosis, tumour 7 at relapse, and tumour 25) with gain of this region as revealed by CGH, showed gains of three of the analyzed genes, SH2D1A, MAGE1 and MTCP1 by densitometric analysis (Figure 3) . However, no amplifications of any of these genes were found in tumor samples with normal CGH profiles or normal peripheral blood samples.
The FISH analysis of tumour 7 (corresponding to a male P53 overexpression n = 9 n = 17 0.037 1 9
Proliferative index n = 10 n = 18 0.003661
n, number of patients in whom clinical and prognostic parameters could be obtained.
patient) using the X-centromere probe and the MAGE1 probe showed that 65% of the nuclei displayed two signal for the X chromosome and four to five signals for the MAGE1 gene (Figure 2) , thus corroborating the CGH and Southern results.
Figure 3
Southern blot analysis of the SH2D1A located in Xq26-28 and the control gene (␤-actin), performed in three tumors with gain of this region (cases 7a, 7b and 25), two lymphomas with CGH normal profiles of X chromosome (cases 3 and 26) and normal sample of peripheral blood (PB). The sex of the patients is also shown (M, male; F, female). The expected gene copy number in the three tumors is represented below the bands.
Discussion
In contrast with B cell NHL, cytogenetic analysis of T cell NHL reveals only a weak relationship between cytogenetic findings and histopathological classification. Moreover, except for some cytogenetic results, such as the presence of an additional X chromosome, structural aberrations of the short arm of chromosome 1 and complex karyotypes, associated with a poor prognosis, 13 little is known about the prognostic impact of chromosome abnormalities in T cell NHL. This lack of information is also evident when it comes to CGH studies, while there are different reports about the CGH profile in B-NHL, there are no studies of T-NHL series that have looked for gains or losses of DNA sequences in the genome of these lymphomas.
Due to the scarcity of information about these features, we performed CGH studies on 37 T cell lymphomas, in order to detect cryptic quantitative genetic alterations, that could otherwise have been masked, and try to establish whether quantitative genetic imbalances could have a clinical value.
In all cases, the immunophenotype and morphology was compatible with the diagnosis of T cell lymphomas. To characterize these tumors better, the presence of clonal tumoral cells was analyzed by molecular rearrangements of TCRgamma chain gene. Most of these lymphomas (63%) showed monoclonal rearrangements, a similar percentage to that found in other T cell NHLs series.
We have found a 59% of samples at diagnosis with abnormal profiles, and a ratio of 66% when the relapse samples were included. This is a similar percentage to that reported when cytogenetic techniques were used in these lymphomas, [3] [4] [5] although some cases with normal CGH profiles could in fact be cases with cytogenetic balanced abnormalities (ie balanced translocations).
With regard to the possible correlation between abnormal CGH profile and different subtypes of T cell lymphomas, CGH did not reveal any chromosomal region to be more frequently associated with morphologically defined subtypes, thus reflecting the heterogeneity that characterizes these neoplasms.
The most frequent DNA imbalances of our series were gains involving the whole or part of the chromosome X (19%), with Leukemia the minimal gained region at Xq26-28. Some cytogenetic studies have shown gains of chromosome X in T cell lymphomas, in accordance with our CGH results. Gains of different regions involving chromosomes 3, 7 and X are frequently observed in other types of B cell lymphoid neoplasms: marginal B cell, 14 follicular, 15 diffuse large B cell, 16 mantle cell, and mediastinal thymic B cell lymphomas, 17 suggesting that these regions may include genes associated with lymphoid neoplasms.
Other recurrent gains involved the whole or part of chromosomes 17 (10%), 19 (10%), 20 (10%), and other chromosomal regions as 9q34 (10%) or 11q13 (8%). Thus, CGH studies could provide new information concerning other alterations not found by conventional cytogenetics, such as the gain of 9q34 region, which has rarely been observed in lymphomas.
The most recurrent deletions were found at 13q (10%), and CGH allowed us to identify a small region commonly deleted at 13q14-21. Losses of 13q seem to be frequent in these lymphomas. These deletions have also been frequently detected with CGH in multiple myeloma, 18 breast cancer, and less frequently in other lymphoid malignancies. 14, 19, 20 The minimal deleted region suggests the location of important genes that are probably involved in multiple tumors.
In addition, CGH analysis could help to identify changes occurring during the evolution of the disease. Most of the cases (four out of seven cases) in which we could study serial samples, showed an accummulation of aberrations at relapse. Two of them changed from a normal to an abnormal profile, with gains or losses at the chromosomes more frequently involved in these lymphomas such us the X, 17 or 13q. The other two cases maintained the alterations previously detected in these samples, together with the appearance of new alterations of different genetic regions.
Southern blot analysis has been used to confirm amplifications of specific genes encoded in chromosomal regions showing genomic gains by CGH technique. 21 In the present study, gain of Xq26-28 region detected by CGH was confirmed by Southern blot and FISH analysis of three genes located on it (SH2D1A, MAGE1, MTCP1), corroborating the CGH results. In addition, gains detected by CGH in this region corresponded to low level amplifications, and the same genetic event (two-to three-fold gain) was found with probes corresponding to that particular regions by the Southern blot and the FISH analysis (Figure 2) .
In general, amplifications or deletions of specific regions suggest that important genes located in these chromosomal regions are possibly involved in the tumoral pathogenesis of tumors. In this way, several genes with importance in the biology and pathology of B-NHL have now been associated with specific regions, such as REL (2p13), BCL-6 (3q27), MYC (8q24), TEL (12p13) or BCL-2 (18q21). We searched the genetic databases for genes located in the most important regions with gains or losses in the T cell lymphomas. The Xq26-28 region contains near 130 known genes and 80 ESTs, some of them clearly related to cancer. In fact, the genes that we have analyzed have been defined as oncogenes and are altered in different neoplasms, including some T cell leukemias. 22 With regard to clinical presentation, evolution and prognosis, cases with normal and abnormal CGH profiles showed different clinical patterns, whereby a higher incidence of cases with advanced disease (stages III-IV), overexpression of P53 protein and increased proliferative index were observed in cases with altered CGH profiles compared with those with normal CGH profiles. These differences were statistically sig-nificant and, therefore, CGH analysis could be used as an index for diagnosis.
To date, this is the first CGH study in T cell NHLs. Our results provide important and previously unknown information about the quantitative genetic abnormalities involved in tumoral pathogenesis of T cell NHLs. CGH confirmed the implication of gains of chromosome X in T cell NHLs, previously reported from the use of cytogenetic techniques, 4, 5 and identified other chromosomes with gains or deletions, allowing us to define more accurately the commonly gained regions as bands Xq26-q28, 19q13.1, 9q34, 11q13, 17q12-q21 or 13q14-q21, although more studies are necessary to clarify the role of the genes located in these regions.
